# Beijing StoneWise Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-stonewise-technology-co

- Industry: Healthcare IT
- Headquarters: Beijing, China
- Website: www.stonewise.cn
- Total disclosed funding: $100M
- Latest round: Series B (Apr 11, 2021)
- Investors on record: 9

## About

Beijing StoneWise Technology Co., Ltd. is a Chinese company focusing on AI-driven software solutions for the pharmaceutical research sector, streamlining drug discovery processes through advanced technical tools and systems.Founded in 2018, Beijing StoneWise Technology Co., Ltd. specializes in AI software solutions for pharmaceutical research. The company has executed a total of 4 deals, with its most recent funding round occurring on April 11, 2021, where it raised USD 100.00 mn in SERIES B funding. The company is led by CEO Jielong Zhou, who continues to guide its strategic direction.Beijing StoneWise Technology Co., Ltd. specializes in advanced AI-driven software solutions designed for the pharmaceutical research and development sector. The company's core product offerings include a high-throughput molecular screening system, a multi-dimensional molecular generation system, and a molecular optimization system based on a mapping database. These innovative tools enable researchers to rapidly identify, analyze, and optimize chemical structures from a variety of sources such as patents and academic literature, significantly reducing the time and effort required in the drug discovery process. The software is specifically aimed at pharmaceutical companies and research institutions seeking to enhance efficiency in chemical structure data processing and to build proprietary databases tailored to their specific research needs. Market presence is noted in regions with robust pharmaceutical research activities, including North America, Europe, and parts of Asia, where the demand for streamlined drug development processes is high.Beijing StoneWise Technology Co., Ltd. operates on a business model that includes subscription-based services and partnerships with research institutions and pharmaceutical companies. Clients engage with the company by subscribing to access its suite of AI software tools, which facilitate the rapid extraction of chemical structures and analysis of associated data. These transactions typically involve annual or multi-year commitments, providing ongoing access to software updates and support. Specific pricing structures are not disclosed, but the company’s flagship products are positioned competitively to meet the needs of industry professionals, ensuring a steady revenue stream from its client base. The company fosters relationships with its users through direct support and collaborative projects, further solidifying its market position in the pharmaceutical research landscape.In April 2021, Beijing StoneWise Technology Co., Ltd. raised USD 100.00 mn in SERIES B funding co-led by new investors Greater Bay Area Homeland Investments Limited, Legend Capital, and Lightspeed Venture Partners, with participation from other new investors CDH Investments and Eastern Bell Capital. The company plans to utilize this funding to recruit global talent and further develop its AI technology and platform. Future initiatives include the introduction of new product offerings tailored to enhance drug development efficiency and expansion into new geographic markets, with specific focus on enhancing presence in North America and Europe by 2023.

## Funding rounds

- Series B, Apr 11, 2021, $100M — Lightspeed Venture Partners, Legend Capital, CDH Investments, SIG Asia Investment, Eastern Bell Capital, Linear Capital, Long Hill Capital, GL Ventures, Greater Bay Area Homeland Investments Limited
- Series A, Sep 9, 2020 — Linear Capital, GL Ventures
- Series A, Mar 16, 2020 — Linear Capital, Long Hill Capital
- Angel, Jul 3, 2018 — SIG Asia Investment

## Investors

- SIG Asia Investment (https://capitalatlas.ai/funds/sig-asia-investment) — Angel, Series B
- Linear Capital (https://capitalatlas.ai/funds/linear-capital) — Series A, Series B
- Long Hill Capital (https://capitalatlas.ai/funds/long-hill-capital) — Series A, Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A, Series B
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series B
- Legend Capital — Series B
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series B
- Eastern Bell Capital — Series B
- Greater Bay Area Homeland Investments Limited (https://capitalatlas.ai/funds/greater-bay-area-homeland-investments-limited) — Series B